Objective      To evaluate the differences on the efficacy and safety of sublingual immunotherapy (SLIT) of vaccine for dust mite allergies on the patients with allergic rhinitis (AR) of different ages living in the Southwest China. Methods     A total of 92 AR patients living in Southwest China who were sensitized to house dust mites and given SLIT for more than 1 year were followed up through telephone and E-mail during January 2014 to January 2015. The patients were divided into 2 groups: child and adolescent groups (5 to 18 years old

n=42) and adult group (19 to 57 years old

n=50). The total nasal symptom scores (TNSS) and adverse events were recorded and analyzed between the 2 groups before

and in 3 and 6 months and 1 year after treatment.  Results     The TNSS was in a declining trend in the both 2 groups. Before and in 3 and 6 months and 1 year after SLIT treatment

the average score was 8.53±1.31

5.82±1.05

2.14±1.17 and 1.03±0.88

respectively in the child and adolescent group

and 8.64±1.35

6.05±1.33

2.64±1.35 and 1.16±0.89 separately in the adult group. Significant differences were seen in the TNSS scores in the 2 groups before and after the treatment (P0.05)

but not between the 2 groups at the same time points (P0.05). There were no sever adverse events occurred in both groups during the first 3 months of SLIT

but 10 cases mild adverse events were observed

with 8 cases from the child and adolescent group (8/42) and 2 cases out of the adult group (2/50

P0.05). Both groups had no adverse events occurred after 3 months’ treatment. Conclusion    SLIT of vaccine for dust mite allergies shows reliable efficacy and safety in the treatment of AR patients at different ages. But children and adolescents might be prone to mild adverse events in the first 3 months of treatment. SLIT is suitable for AR patients of different ages.